Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Drug distribution within solid tumours is an often-neglected area of research in chemotherapeutic resistance. This Review summarizes the evidence that many chemotherapeutic drugs do not completely penetrate tumours, and suggests strategies to circumvent this problem.
Microarray analyses have enabled tumours to be grouped on the basis of their genomic alterations rather than their tissue of origin. But does the identification of lineage-survival genes implicate lineage dependency (or lineage addiction) as a mechanism that is also affected by tumour genetic alterations?
The role of cancer registries has expanded from the description of incidence trends to calculating survival and individual care management. Now, 21% of the world’s population is covered by registries, and this review surveys the global situation.
Recent advances in the understanding of tumour–host interactions have revealed some key effectors of tumoral immune escape that limit the successful use of treatments that rely on boosting immune function. Can some of these effectors be targeted by small-molecule inhibitors?
Biomarkers used in determining the response to cytotoxic agents are not optimal for predicting benefit from anti-angiogenic drugs. Which anti-angiogenic biomarkers might prove useful for identifying initial drug choice, appropriate dosing, early clinical benefit, emerging resistance and second-line treatments?
Recent findings have indicated that the tyrosine-kinase receptor MET is a sensor of adverse microenvironmental conditions (such as hypoxia), and can drive cell invasion and metastasis through the transcriptional activation of a set of genes that control blood coagulation.
The new French National Cancer Institute (INCa) has brought cancer care, research and policy in France together for the first time. Three years after its conception, and one year after its inauguration, this article charts its aims and structure.